MM-II OSTEOARTHRITIS DRUG PIPELINE – MARKET INSIGHTS AND FORECASTS UPTO 2032
MM-II is a new non-opioid intra-articular injection designed to alleviate knee pain in patients with osteoarthritis. Get more insights into our latest reports
LORECIVIVINT OSTEOARTHRITIS DRUG PIPELINE – MARKET INSIGHTS AND FORECASTS UPTO 2032
Lorecivivint (SM04690) is a small-molecule inhibitor targeting the Wnt pathway, delivered through intra-articular injection. Get more insights into our reports
INVOSSA OSTEOARTHRITIS DRUG PIPELINE – MARKET INSIGHTS AND FORECASTS UPTO 2032
INVOSSA is a groundbreaking cell and gene therapy designed to treat knee osteoarthritis with a single intra-articular injection. Request Free Sample Report
LNA043 OSTEOARTHRITIS DRUG PIPELINE – MARKET INSIGHTS AND FORECASTS UPTO 2032
LNA043 is an innovative ANGPTL3 agonist designed to specifically target and repair damaged cartilage. Read more about LNA043 Osteoarthritis pipeline report
SPRIFERMIN OSTEOARTHRITIS DRUG PIPELINE – MARKET INSIGHTS AND FORECASTS UPTO 2032
Sprifermin (AS-902330) is a recombinant version of human fibroblast growth factor 18 (FGF18). Get more insights into Sprifermin Osteoarthritis pipeline report